Ikarian Capital, LLC Infla Rx N.V. Transaction History

Ikarian Capital, LLC

$573 Million
Q3 2024

A detailed history of Ikarian Capital, LLC transactions in Infla Rx N.V. stock. As of the latest transaction made, Ikarian Capital, LLC holds 704,987 shares of IFRX stock, worth $1.83 Million. This represents 0.19% of its overall portfolio holdings.

Number of Shares

704,987

Previous 704,987 -0.0%

Holding current value

$1.83 Million

Previous $1.23 Million 12.07%

% of portfolio

0.19%

Previous 0.5%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$1.47 - $2.03 $24,083 - $33,257	16,383 Added 2.38%	704,987 $1.09 Million
Q3 2023 Nov 14, 2023	BUY	$2.66 - $4.33 $1.83 Million - $2.98 Million	688,604 New	688,604 $2.05 Million
Q2 2022 Aug 12, 2022	SELL	$0.78 - $1.9 $272,585 - $663,989	-349,468 Closed	0 $0
Q1 2022 May 13, 2022	BUY	$1.83 - $4.48 $33,708 - $82,521	18,420 Added 5.56%	349,468 $639,000
Q4 2021 Feb 14, 2022	SELL	$2.35 - $5.58 $705,000 - $1.67 Million	-300,000 Reduced 47.54%	331,048 $1.58 Million
Q3 2021 Nov 15, 2021	SELL	$2.25 - $3.03 $79,983 - $107,710	-35,548 Reduced 5.33%	631,048 $1.63 Million
Q2 2021 Aug 16, 2021	SELL	$2.72 - $4.04 $90,178 - $133,942	-33,154 Reduced 4.74%	666,596 $1.98 Million
Q1 2021 May 17, 2021	BUY	$3.62 - $6.34 $1.99 Million - $3.49 Million	550,000 Added 367.28%	699,750 $2.73 Million
Q3 2020 Nov 16, 2020	SELL	$3.7 - $5.47 $10,545 - $15,589	-2,850 Reduced 1.87%	149,750 $637,000
Q2 2020 Aug 14, 2020	SELL	$4.59 - $8.96 $504,900 - $985,600	-110,000 Reduced 41.89%	152,600 $700,000
Q1 2020 May 15, 2020	SELL	$2.65 - $6.08 $255,799 - $586,890	-96,528 Reduced 26.88%	262,600 $1 Million
Q4 2019 Jan 31, 2020	BUY	$2.2 - $4.54 $790,081 - $1.63 Million	359,128 New	359,128 $1.42 Million

Others Institutions Holding IFRX

# of Institutions

Shares Held

12.9M

Call Options Held

19.3K

Put Options Held

View Full List

About InflaRx N.V.

Ticker IFRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 44,203,800
Market Cap $114M
Description
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a nov...

More about IFRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ikarian Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Ikarian Capital, LLC with notifications on news.

Account

Ikarian Capital, LLC Infla Rx N.V. Transaction History